Eli Lilly’s retatrutide Phase 3 results have brought fresh attention to an investigational treatment targeting three hormone receptors involved in metabolic regulation. In results announced on 23 July 2026, Lilly reported average weight reductions of up to 22.6% across two additional late-stage trials.
The studies, TRIUMPH-2 and TRIUMPH-3, evaluated different populations: people with type 2 diabetes and people with a body mass index of at least 35 plus cardiovascular disease. Both reported greater average weight reductions with retatrutide than with placebo. However, the findings also require careful interpretation, particularly around cardiovascular outcomes, treatment discontinuations and the limits of comparisons between trials.
Retatrutide remains investigational and is not FDA-approved. Lilly plans to submit a biologics license application in the first quarter of 2027. That planned filing is a regulatory milestone, not an approval date or a guarantee of commercial availability.
What Is Retatrutide?
Retatrutide is an investigational triple GIP, GLP-1 and glucagon receptor agonist. This means it is designed to activate three distinct hormone receptors involved in metabolic processes.
Its three-receptor mechanism distinguishes it from treatments that act on one or two of these pathways. However, a broader mechanism does not, by itself, establish better effectiveness or safety. Those questions depend on clinical trial evidence and regulatory assessment.
The Phase 3 TRIUMPH programme is evaluating retatrutide in defined patient populations. The latest results add evidence about weight change, blood sugar measures and safety, but they do not establish that the compound is suitable for any particular individual.
Retatrutide Phase 3 Results at a Glance
The July 2026 announcement covered two trials with different participant characteristics. Keeping those differences in view is essential when interpreting the headline numbers.
- TRIUMPH-2: Enrolled 1,152 participants with type 2 diabetes and evaluated outcomes over 80 weeks.
- TRIUMPH-2 weight results: The reported retatrutide group had an average weight reduction of 20.8%, compared with 4.0% for placebo.
- TRIUMPH-2 blood sugar results: A1C fell by 1.5 percentage points with retatrutide, compared with 0.2 percentage points with placebo.
- TRIUMPH-3: Enrolled 1,949 participants with a BMI of at least 35 and cardiovascular disease.
- TRIUMPH-3 weight results: The reported retatrutide group had an average weight reduction of 22.6%, compared with 3.2% for placebo.
These figures describe average changes in study groups. They are not predictions of an individual response and should not be read as guaranteed outcomes.
TRIUMPH-2: Findings in People With Type 2 Diabetes
TRIUMPH-2, registered as NCT05929079, investigated retatrutide in 1,152 participants with type 2 diabetes. Over 80 weeks, the reported retatrutide group experienced an average weight reduction of 20.8%, while the placebo group experienced a 4.0% reduction.
The difference between those reported averages was 16.8 percentage points. This helps distinguish the total weight change observed in the retatrutide group from the additional change relative to placebo.
What the A1C Result Means
Lilly also reported an A1C reduction of 1.5 percentage points with retatrutide, compared with 0.2 percentage points with placebo. A1C is a measure used to assess average blood glucose over time.
The wording matters: a reduction of 1.5 percentage points is not the same as a 1.5% relative reduction. Nor does the reported change alone reveal every participant’s final A1C level or establish that all participants reached a particular blood sugar target.
Together, the weight and A1C findings provide evidence about retatrutide in the population studied. They should not automatically be extended to people with different clinical characteristics.
TRIUMPH-3: Understanding the 22.6% Weight Loss Figure
TRIUMPH-3, registered as NCT05882045, enrolled 1,949 participants with a BMI of at least 35 and cardiovascular disease. Lilly reported an average weight reduction of 22.6% with retatrutide, compared with 3.2% for placebo.
The difference between those group averages was 19.4 percentage points. Importantly, the 22.6% figure represents the reported average reduction in the retatrutide group, not an additional 22.6% reduction beyond placebo.
The phrase up to 22.6% weight loss refers here to the higher reported group average across these two trials. It does not describe the maximum individual weight loss, and it does not mean every participant lost that amount.
Why the Two Trials Should Not Be Ranked Directly
TRIUMPH-2 and TRIUMPH-3 enrolled different populations. Their results should therefore not be treated as a direct comparison showing that retatrutide works better in one condition than another.
For the same reason, these findings do not establish superiority over another weight-management medicine. Comparisons across separate studies can be affected by differences in participants, study design and analysis methods. A direct comparative trial would be needed to answer a head-to-head question reliably.
Did Retatrutide Demonstrate a Cardiovascular Benefit?
The cardiovascular findings require more caution than the weight-loss headline. For the MACE-5 cardiovascular endpoint in TRIUMPH-3, Lilly reported a hazard ratio of 0.82, with a 95% confidence interval of 0.55 to 1.22.
Although the point estimate was below 1, the confidence interval included 1. The reported result therefore does not establish a statistically significant reduction in that cardiovascular endpoint.
It would be misleading to turn this finding into a claim that retatrutide has proven cardiovascular protection. Weight change and cardiovascular event outcomes are distinct measures, and evidence for one should not be substituted for evidence about the other.
Safety and Treatment Discontinuations
Effectiveness is only one part of evaluating an investigational treatment. Tolerability and adverse events also influence how trial findings are assessed.
The supplied results reported adverse-event-related discontinuation of 13.5% in the retatrutide group, compared with 4.8% with placebo. These figures indicate that a greater proportion of participants in the reported retatrutide group stopped treatment because of adverse events.
Discontinuation rates do not provide a complete safety profile. They do not, on their own, explain every event’s type, severity, timing or relationship to treatment. Detailed safety findings remain important to understanding the balance between the observed benefits and risks.
FDA Filing Planned for the First Quarter of 2027
Lilly has stated that it plans to submit a biologics license application in Q1 2027. The distinction between a planned application and an approved treatment is important.
- A filing plan is forward-looking: It describes an intended submission timeline.
- A submission is not approval: The FDA must assess the application before making a regulatory decision.
- Availability is not established: A planned filing does not confirm a launch date, final prescribing information or approved uses.
Until a regulatory decision is made, retatrutide should be described plainly as investigational, rather than as an available or approved weight-management treatment.
The Bottom Line on Retatrutide Phase 3 Results
The latest Eli Lilly retatrutide results reported substantial average weight reductions in two Phase 3 populations: 20.8% in TRIUMPH-2 and 22.6% in TRIUMPH-3. TRIUMPH-2 also reported a greater A1C reduction than placebo.
Those findings sit alongside important qualifications. Individual responses vary, adverse-event-related discontinuations were higher in the reported retatrutide group, and the cardiovascular result did not establish a statistically significant benefit. With an FDA filing planned for early 2027, regulatory review remains a future step rather than a completed milestone.
This article is informational and discusses an unapproved investigational compound. It does not provide medical advice or treatment instructions.
